NEW YORK (GenomeWeb News) – Rules-Based Medicine said today it will work with start-up drug firm Psynova Neurotech to develop and sell a biomarker-based blood test that could be used to help diagnose schizophrenia. 
The companies will work together to validate, seek regulatory approval for, and manufacture the schizophrenia test, which RBM will sell exclusively worldwide.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.